#Srdx website update#
#Srdx website trial#
#Srdx website download#
#Srdx website free#

SRDX currently has a PEG ratio of 24.78.Īnother notable valuation metric for HRC is its P/B ratio of 4.77. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. We also note that HRC has a PEG ratio of 2.57. HRC currently has a forward P/E ratio of 21.63, while SRDX has a forward P/E of 247.77.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. But this is only part of the picture for value investors. Investors should feel comfortable knowing that HRC likely has seen a stronger improvement to its earnings outlook than SRDX has recently. Right now, Hill-Rom is sporting a Zacks Rank of #2 (Buy), while SurModics has a Zacks Rank of #4 (Sell). The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. To read this article on click here.Investors with an interest in Medical - Products stocks have likely encountered both Hill-Rom (HRC) and SurModics (SRDX).

#Srdx website free#

Medtronic PLC (MDT) : Free Stock Analysis Report Click to get this free reportĪbbott Laboratories (ABT) : Free Stock Analysis Report

#Srdx website download#

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. You can see the complete list of today’s Zacks #1 Rank stocks here. Lantheus has declined 24.2% against the industry’s 1% growth in the past six months.

LNTH’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 51.09%. Lantheus has an estimated earnings growth rate of 10% for 2023. Lantheus LNTH is a better-ranked stock to consider from the same industry, sporting a Zacks Rank #1 (Strong Buy). Surmodics currently carries a Zacks Rank #3 (Hold). Per Medtronics website, IN.PACT Admiral DCB is the market-leading DCB that has demonstrated durable, consistent, and safe outcomes across multiple clinical trials. A 24-month data from the TRANSCEND study demonstrated continuous improvement in functional outcomes for treated patients, which was comparable to Medtronic’s IN.PACT Admiral DCB. SurVeil DCB also delivered a substantially lower drug dose versus MDT’s IN.PACT Admiral DCB.

#Srdx website trial#

Data from the TRANSCEND 12-month pivotal clinical trial showed that SurVeil DCB met both the primary safety and primary efficacy endpoints that were found to be non-inferior compared to Medtronic’s IN.PACT Admiral DCB. TRANSCEND Study Dataĭata from the TRANSCEND study demonstrated compelling performance for SurVeil DCB. The study compared the results with Medtronic’s MDT IN.PACT Admiral DCB, which was evaluated in the comparator-arm, for non-inferiority.

The study evaluated the safety and efficacy of SurVeil DCB, a next-generation device for the treatment of peripheral artery disease (PAD). The company completed the submission of the PMA application for SurVeil DCB in the third quarter of 2021, based on data from clinical trial - TRANSCEND. Surmodics announced last week that it has received a letter from the FDA indicating that a premarket approval (“PMA”) application for its SurVeil DCB is not currently approvable. The S&P 500 Index has declined 0.4% in the same time period. In fact, the company’s shares have declined 33.3% in the past six months against the industry’s 0.9% increase.

#Srdx website update#

SRDX have declined 31.8% since the close on Jan 18, following disappointing regulatory update related to its SurVeil drug-coated balloon (“DCB”).